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 Abstract 
 Background: The 2009 Asian multicenter study for deri-
vation of reference intervals (RIs) featured: 1) centralized 
measurements to exclude reagent-dependent variations; 
2) inclusion of non-standardized analytes (hormones, 
tumor makers, etc.) in the target; and 3) cross-check of 
test results between the central and local laboratories. 
Transferability of centrally derived RIs for non-standard-
ized analytes based on the cross-check was examined. 
 Methods: Forty non-standardized analytes were centrally 
measured in sera from 3541 reference individuals recruited 
by 63 laboratories. Forty-four laboratories collaborated in 
the cross-check study by locally measuring aliquots of 
sera from 9 to 73 volunteers (average 22.2). Linear rela-
tionships were obtained by the reduced major-axis regres-
sion. Error in converting RIs using the regression line was 
expressed by the coefficient of variation of slope b [CV(b)]. 
CV(b)  < 10% was set as the cut-off value allowing the con-
version. The significance of factors for partitioning RIs 
was determined similarly as in the first report. 
 Results: Significant sex-, age-, and region-related changes in 
test results were observed in 17, 15, and 11 of the 40 analytes, 
respectively. In the cross-comparison study, test results were 
not harmonized in the majority of immunologically meas-
ured analytes, but their average CV(b)s were  < 10% except 
for total protein, cystatin C, CA19-9, free thyroxine, and tri-
iodothyronine. After conversion, 74% of centrally derived 
RIs were transferred to each local laboratory. 
 Conclusions: Our results point to the feasibility of: 1) har-
monizing test results across different laboratories; and 2) 
sharing centrally derived RIs of non-standardized ana-
lytes by means of comparative measurement of a set of 
commutable specimens. 
 Keywords:  harmonization;  immunoassays;  multicenter 
study;  standardization. 
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 Non-standard abbreviations 
 ADP, adiponectin; AFP,  α -fetoprotein; ApoA1, apolipopro-
tein A-I; ApoB, apolipoprotein B; ApoE, apolipoprotein E; 
ASO, anti-streptolysin O; BAP, bone alkaline phosphatase; 
BC, Beckman Coulter; CA15-3, carbohydrate antigen 15-3; 
CA19-9, carbohydrate antigen 19-9; CA125, carbohydrate 
antigen 125; CEA, carcinoembryonic antigen; CV(b), coef-
ficient of variation of slope  ‘ b ’ ; CysC, cystatin C; DHEA-S, 
dehydroepiandrosterone sulfate; EPO, erythropoietin; Fe, 
iron; Ferritin, ferritin; Folate, folic acid; FSH, follicle-stim-
ulating hormone; FT3, free triiodothyronine; FT4, free thy-
roxine; IgE, immunoglobulin E; IP, inorganic phosphate; 
JSCC, Japan Society of Clinical Chemistry; LH, luteinizing 
hormone; LIP, lipase; LL, lower limit; Lp(a), lipoprotein 
(a); PG1, pepsinogen I; PG2, pepsinogen II; PRL, prolac-
tin; PSA, prostate-specific antigen; PTH, intact parathy-
roid hormone; RBP, retinol-binding protein; RI, reference 
interval; SAA, serum amyloid A; SE, standard error; sTf-R, 
soluble transferrin receptor; TG, thyroglobulin; TP, protein, 
total; TRAP-5b, tartrate-resistant acid phosphatase 5b; TSH, 
thyroid-stimulating hormone; UIBC, unsaturated iron-
binding capacity; UL, upper limit; VitB12, vitamin B12. 
 Introduction 
 There has been growing demand for the conduction of 
a multicenter study to derive reference intervals (RIs) of 
commonly ordered laboratory tests that have been glob-
ally standardized. The Asian multicenter study conducted 
in 2009 was unique in that it also attempted to derive 
common RIs for non-standardized analytes, such as 
protein hormones and tumor markers, most of which 
were measured by immunoassays [ 1 ]. The key strategy 
was to centralize measurement by transporting all serum 
specimens in a deep-frozen state to central laboratories 
located in Japan. A single reagent and platform for each of 
the analytes was used to detect regionality of test results 
without assay-related variations. 
 The policy was appropriate for the standardized ana-
lytes such as creatinine, uric acid, total cholesterol, and 
electrolytes. However, for the non-standardized analytes, 
each RI determined was only relevant to the laboratories 
that used the same reagents as the central laboratory. 
Therefore, a scheme was implemented to cross-compare 
test results between the central and collaborating labora-
tories. For this purpose, parts of the frozen aliquots of sera 
remained at each laboratory and were measured locally. 
We: 1) analyzed sex-, age-, and region-related changes in 
test results for 40 non-standardized analytes; 2) derived 
their RIs for the central laboratory; and 3) evaluated the 
transferability of the RIs to each collaborating laboratory 
on the basis of cross-check testing. 
 Materials and methods 
 Multicenter study conducted in East and 
Southeast Asian 
 The framework of the Asian multicenter study was described in the 
companion paper, Part 1 of this article [ 1 ]. In brief, 48 laboratories 
from 14 cities distributed widely from the north to the south of Japan, 
and 15 laboratories in nine cities outside Japan (Seoul, Beijing, Taipei, 
Tainan, Hong Kong, Macau, Ho Chi Minh City, Kuala Lumpur, and Ja-
karta) took part in the study. A total of 3541 healthy individuals (2082 
from Japan and 1459 from outside Japan) between 20 and 64 years of 
age were recruited using common criteria, and samples of their blood 
were drawn at basal conditions. Aft er a selection process for excluding 
those with apparent abnormal results in basic screening test items such 
as TG, HDL-C, glucose, etc., was performed, test results from a total of 
3314 subjects (1438 males, 1876 females) were served for data analyses. 
Names, abbreviations, assay methods, and imprecision of the analytes 
for which test results were evaluated in this report are listed in  Table 1 . 
 Collection and measurement of specimens 
for cross-check testing 
 The standard amount of blood taken from each volunteer was 17 mL 
(8.5 mL/tube  × 2). The tubes, Vacutainer SST (capacity: 8.5 mL) con-
taining a clot-activator, were provided by Becton-Dickinson Corp. 
(Franklin Lakes, NJ, USA). Sera were separated into CryoTube cryovials 
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 Table 1   List of assay methods and assay imprecision near the mid-normal range. 
 Abbr  Analytes  Method  Reagent  Analyzer  Within-
day CV, % 
 Between-
day CV, % 
 TP  Protein, total  Timed endpoint biuret method  BC  (1)  0.76  1.49 
 CysC  Cystatin C  Latex immunoturbidimetric method  NM  (1)  1.54  2.56 
 IP  Inorganic phosphate  Timed endpoint molybdate UV method  BC  (1)  1.55  0.00 
 Fe  Iron  Timed endpoint direct colorimetry  BC  (1)  1.97  1.46 
 UIBC  Unsaturated iron-binding capacity  Timed endpoint direct colorimetry  BC  (1)  1.74  2.18 
 Apo A1  Apolioprotein A-I  Turbidimetric method  BC  (1)  1.91  3.72 
 Apo B  Apolioprotein B  Turbidimetric method  BC  (1)  1.56  2.59 
 Apo E  Apolioprotein E  Turbidimetric immunoassay  NM  (1)  1.62  2.71 
 Lp(a)  Lipoprotein (a)  Turbidimetric immunoassay  NM  (1)  1.74  3.03 
 LIP  Lipase  Enzymatic rate method  BC  (1)  2.36  3.43 
 IgE  Immunoglobulin E  Chemiluminescent enzyme immunoassay  BC  (2)  2.61  2.17 
 SAA  Serum amyloid A  Latex immunoturbidimetric method  EM  (1)  1.64  2.63 
 RBP  Retinol-binding protein  Latex immunoturbidimetric method  NM  (1)  1.78  3.20 
 ASO  Anti-streptolysin O  Turbidimetric immunoassay  BC  (1)  1.83  3.34 
 sTf-R  Soluble transferin receptor  Chemiluminescent enzyme immunoassay  BC  (2)  1.30  1.50 
 Ferritin  Ferritin  Chemiluminescent enzyme immunoassay  BC  (2)  1.79  2.01 
 EPO  Erythropoiein  Chemiluminescent enzyme immunoassay  BC  (2)  1.74  1.76 
 VitB12  Vitamin B12  Chemiluminescent enzyme immunoassay  BC  (2)  3.33  2.36 
 Folate  Folic acid  Chemiluminescent enzyme immunoassay  BC  (2)  1.68  0.77 
 AFP  α -fetotein  Chemiluminescent enzyme immunoassay  BC  (2)  2.00  1.90 
 CEA  Carcinoembryonic antigen  Chemiluminescent enzyme immunoassay  BC  (2)  3.03  2.49 
 CA19-9  Carbohydrate antigen 19-9  Chemiluminescent enzyme immunoassay  BC  (2)  3.44  5.46 
 CA15-3  Carbohydrate antigen 15-3  Chemiluminescent enzyme immunoassay  BC  (2)  1.94  2.51 
 CA125  Carbohydrate antigen 125  Chemiluminescent enzyme immunoassay  BC  (2)  2.57  2.16 
 PSA  Prostate-specific antigen  Chemiluminescent enzyme immunoassay  BC  (2)  2.54  3.03 
 PG1  Pepsinogen I  Latex immunoturbidimetric method  EM  (3)  1.61  2.70 
 PG2  Pepsinogen II  Latex immunoturbidimetric method  EM  (3)  1.55  2.58 
 DHEA-S  Dehydroepiandrosterone sulfate  Chemiluminescent enzyme immunoassay  BC  (2)  1.52  1.46 
 PRL  Prolactin  Chemiluminescent enzyme immunoassay  BC  (2)  1.16  0.98 
 LH  Luteinizing hormone  Chemiluminescent enzyme immunoassay  BC  (2)  2.64  1.95 
 FSH  Follicle-stimulating hormone  Chemiluminescent enzyme immunoassay  BC  (2)  2.68  1.80 
 TSH  Thyroid-stimulating hormone  Chemiluminescent enzyme immunoassay  BC  (2)  2.23  1.53 
 FT4  Free thyroxine  Chemiluminescent enzyme immunoassay  BC  (2)  2.07  2.14 
 FT3  Free triiodothyronine  Chemiluminescent enzyme immunoassay  BC  (2)  1.95  1.05 
 Tg  Thyroglobulin  Chemiluminescent enzyme immunoassay  BC  (2)  1.95  1.88 
 Insulin  Insulin  Chemiluminescent enzyme immunoassay  BC  (2)  1.75  2.06 
 ADP  Adiponectin  Latex immunoturbidimetric method  OP  (3)  1.64  2.76 
 PTH  Intact parathyroid hormone  Chemiluminescent enzyme immunoassay  BC  (2)  1.92  1.76 
 BAP  Bone alkaline phosphatase  Chemiluminescent enzyme immunoassay  BC  (2)  1.85  1.98 
 TRAP-5b  Tartrate-resistant acid 
phosphatase 5b 
 Enzyme immunoassay  NM  (4)  1.62  2.71 
 BC, Beckman Coulter; EM, Eiken Medical; NM, Nitobo Medical; OP, Otsuka Pharma. (1) UniCell DxC, BC, Japan (2) UniCell DxI, BC, Japan 
(3) JCA-BM 6050, JEOL Ltd, Japan (4) Manual. 
(capacity: 4.8 mL) (Nunc, Roskilde, Denmark), and put into deep free-
zer immediately as described in the fi rst part of this paper. 
 Among the 63 collaborating laboratories, 44 voluntarily took 
part in the exercise of cross-check testing for secondary transference 
of RIs. Those volunteers who agreed to cooperate in the cross-check 
testing scheme gave one additional tube of blood (8.5 mL). These ad-
ditional specimens were processed and stored identically with the 
other specimens to be transported to the central laboratory in Japan. 
The number of specimens used for the cross-check ranged from 9 to 
73 (average 22.2). A total of 65 analytes, including standardized ana-
lytes for which RIs and related data analysis were reported [ 1 ], were 
available for the cross-comparison of test results. 
 The frozen specimens stored at ‒80 ° C were thawed and meas-
ured identically with specimens for routine assay under well-con-
trolled condition during the period when the collective measure-
ments were being conducted. The test results recorded in an Excel 
fi le together with assay methods, reagents, and assay platforms were 
sent to the Secretariat of this study located at the Ichihara Research 
Laboratory in the Yamaguchi University Graduate School of Medi-
cine, Ube, Japan. 
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 Quality control of the assays 
 Quality control (QC) monitoring in the central laboratory was carried 
out chiefl y by use of a set of four fresh-frozen pooled sera from healthy 
individuals, stored in aliquots at  − 80 ° C. Additional seven sets of com-
mercially available QC specimens with artifi cially adjusted matrix were 
also measured as a supplemental monitoring procedure (Supplementa-
ry Table 1, which accompanies the article at http://www.degruyter.com/
view/j/cclm.2013.51.issue-7/issue-fi les/cclm.2013.51.issue-7.xml). Each 
set of QC specimens consisted of two to three levels (below, within, or 
above the normal level). Two sets were for chemically measured tests 
and the other fi ve were for the immunologically measured tests. The 
same sets of specimens were also distributed to the local laboratories 
that took part in the cross-check study. The test results of commercial QC 
sera were reported together with those of specimens for the cross check. 
 Statistical analysis 
 Analysis of sources of variation and derivation of RIs were performed 
in the exact same way as described in Part 1 of this paper [ 1 ]. The lin-
ear structural relation of test results between the central laboratory 
and each local laboratory was determined by use of the major axis 
regression method [ 2 – 4 ], expressed as follows with  x  and  y  and 
 b denoting the averages of  x (test result from the central laboratory) 
and  y (corresponding result from a local laboratory), and the slope, 
respectively. 
  ( ) ( )y y b x x− = × −   (1) 
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 where  n, S xx , and  S yy denote the sample size, and sums of squared-
deviations of values from each of the central and local laboratories, 
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 Using the regression Equation (1), the lower limit (LL) and upper 
limit (UL) of a RI centrally derived can be converted to those of a local 
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 The standard error of the slope  b , SE(b), was determined by the 
bootstrap method by re-sampling the same number of data from the 
original dataset [ 5 ]. Mathematical derivation of SE(b) is known to be 
diffi  cult but it is said to be approximated by the standard error of the 
slope  b ′ , SE(b ′ ), computed by the ordinary least square method using 
the following formula (2, 4) (see Appendix 1). 
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 For standardized comparison of the SE(b), it was expressed as 
the coeffi  cient of variation of slope  b [CV(b)] by taking its ratio to  ‘ b ’ 
as follows: 
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 CV(b) was used as a guide to judge convertibility of the RIs de-
rived from the central laboratory to those of the participating labo-
ratories. Although many factors have to be considered in deciding 
when to allow the conversion, as explained in the Discussion, we 
empirically set CV(b) = 10% as the cut-off  value for the conversion. 
 Results 
 Sources of variations of test results 
 The magnitudes of sex-, age-, and region-specific dif-
ferences in test results examined by three-level nested 
ANOVA are as shown in  Table 2 . We regarded a SD ratio 
(SDR) of   ≥  0.3 of any given factor as significant for consid-
eration of partitioning RIs by the factor, as we did in Part 1 
of this paper. With regard to between-sex difference, we 
compared the judgment by SDR for sex [SDR-sex] (third 
rightmost column in  Table 2 ) with that by the Harris-Boyd 
method employing the adjusted z score [az] (fourth right-
most column in  Table 2 ), whose critical limit is usually 
set as 3.0. The two approaches matched quite well. Sig-
nificant sex-related change was identified by az score and 
SDR-sex in 20 and 17 of 40 analytes, respectively, includ-
ing prominent examples of RBP, ferritin, and PSA. Simi-
larly, significant between-region differences were found 
by SDR for between-region (SDR-reg) in nine analytes, 
including folate, CA15-3, adiponectin, and PTH as notable 
examples ( Figure 1 ). Similar figures are provided for all the 
analytes in Supplemental Figure 1. Age-related changes 
were noted in 15 analytes including ApoB, DHEA-S, LH, 
and FSH. As the magnitude of between-region and -age 
differences often differ between the two sexes, we per-
formed three-level nested ANOVA after separating the 
dataset by sex and introducing BMI as a third factor for the 
analysis (Supplementary Table 2). The two values shown 
within the parenthesis in the last two columns in  Table 
2 represent corresponding SDR-reg and -age values for 
males and females, respectively. We observed unmatched 
region- and age-related changes between the two sexes 
in three analytes (CysC, ferritin, and TRAP-5b) and seven 
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analytes (LIP, CA125, PRL, LH, FSH, BoneALP, and TRAP-
5b), respectively. 
 Reference intervals 
 The RIs derived by the same procedures as described in 
Part 1 of this paper are listed in  Table 3 , and in Supple-
mentary Table 3 for full results for region-specific RIs. The 
age-specific RIs derived for each sex and decade of age are 
listed in Supplementary Table 4. 
 Assay reagents or platforms involved in the 
cross-check testing 
 In this report, those laboratories using  < 15 specimens for 
the comparison were omitted due to lack of adequate sta-
tistical power in the evaluation. Thus, the actual datasets 
used for the evaluation were reduced to those from 37 of 
the original 44 laboratories. Furthermore, those analytes 
with participation of less than eight laboratories for cross-
check testing were also omitted, thus reducing the number 
of analytes actually evaluated to 22 from the original 34. 
 The combinations of reagents and assay platforms 
actually used for the measurements by local laboratories 
were so divergent that we did not list them here. However, 
those analytes measured by immunoassays could be sub-
grouped by manufacturers of assay reagents/platforms 
into a small number of categories as listed in  Table 4 with 
Roche, Abbott, and Tosoh accounting for the majority of 
the immunoassays. 
 Typical two-dimensional scattergrams for 
the cross-check testing 
 Typical cross-check results for four non-standardized 
analytes (AFP, CA19-9, PSA, and TSH) are illustrated in 
 Figure 2 . The x-axis represents test results by the central 
laboratory, and the y-axis represents results obtained 
at three local laboratories (Laboratories 1104, 1501, and 
4103). These results were chosen to demonstrate repre-
sentative results, and their reagents and assay platforms 
differed from those of the central laboratory. The compari-
sons of the values were made based on conventional units 
because the figures are just meant to demonstrate compa-
rability of the values. 
 CV(b)s shown in the left top corner of the graph 
inversely correlated with the correlation coefficients 
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 Figure 1   Regionality of test results observed in four analytes. 
 Each panel consists of two figures, one for males and one for females. Test results were sub-grouped into 14 areas: seven from Japan (blue, 
male; red, female) and another seven from East and Southeast Asia (green, male; orange, female). The regions were aligned from the north 
to the south. The box within the scattergrams represents the central 50% range, and the vertical line in the middle of the box indicates the 
median. 
that CV(b) decreases proportionately with the square 
root of the sample size used for the linear regression as 
expected from Equation (6). As described below, the cross-
comparison for AFP, PSA, and TSH generally resulted in 
close correlations, although regression lines mostly did 
not match with the line of concordance (y = x). However, 
the graphs for CA19-9 showed a large scatter around 
regression lines with larger CV(b)s. 
 The CV(b) list 
 The list of CV(b) computed from the regression line for 
the cross-check between the central laboratory and each 
local laboratory is shown in  Table 5 . The first column 
represents the sequence number of the local laborato-
ries listed. The second column represents the number 
of samples actually measured by each local labora-
tory. Cells are colored according to the magnitude of 
CV(b). The average CV(b) and the percentage of labora-
tories that received the transference service of RIs with 
CV(b)  < 10% are shown in the two bottom rows. A high 
rate of transferability of RI ( > 80%) was attained among 
the participating laboratories in the vast majority of ana-
lytes. Notable exceptions were those for TP, CysC, CA19-9, 
FT4, and FT3, which showed  < 80% transferability. The 
list of CV(b) for the standardized analytes are shown in 
Supplementary Table 5. Their CV(b) were generally low 
except for Alb, Na, K, Cl, and Ca, with a CV(b) exceeding 
10% in most of the cases. 
 Commutability of commercial QC specimens 
in the cross-comparison 
 We had expected that commercial QC specimens would 
give much the same results in the cross-comparison of 
test results between the central and local laboratories. 
However, prominent differences were observed with the 
use of the QC specimens in test results for chloride, inor-
ganic phosphate, HDL-C, LDL-C, amylase, and, partly, 
AST, ALP, sodium, potassium, and total protein.  Figure 3 
shows typical results of the cross-comparison plotted for 
two datasets: one for individual sera (black dots), as in 
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 Table 3   List of RIs derived. 
 International unit  n  Male + Female  n  Male  n  Female 
 Analytes  Units  SDR-reg  Area  LL  Me  UL  LL  Me  UL  LL  Me  UL 
 TP  g/L  0.36  Asia All  2891  64  71  79  1279  64  71  79  1611  64  71  79 
    Japanese  1732  64  71  78  784  64  71  78  948  63  71  78 
    Chinese  601  64  71  79  266  65  71  78  334  64  71  80 
    SE Asia  479  66  74  82  196  66  74  82  283  66  74  82 
 CysC  mg/L  0.28  Asia All  2884  0.63  0.85  1.16  1274  0.71  0.92  1.21  1605  0.61  0.80  1.05 
    Japanese  1725  0.62  0.83  1.12  782  0.69  0.90  1.17  944  0.61  0.78  1.03 
    Chinese  600  0.65  0.87  1.22  267  0.74  0.95  1.31  331  0.62  0.80  1.05 
    SE Asia  477  0.65  0.90  1.21  196  0.79  0.98  1.29  282  0.63  0.84  1.10 
 IP  mmol/L  0.00  Asia All  2889  0.93  1.22  1.54  1278  0.88  1.18  1.50  1610  0.98  1.26  1.55 
 Fe  mmol/L  0.06  Asia All  2888  5  17  33  1271  8  18  34  1609  4  15  32 
 UIBC  mmol/L  0.14  Asia All  2889  21  40  69  1276  19  37  55  1612  24  44  75 
 ApoA1  mg/L  0.45  Asia All  2883  1112  1462  1967  1275  1072  1383  1839  1606  1173  1531  2000 
    Japanese  1724  1175  1513  2017  778  1144  1442  1913  943  1240  1574  2052 
    Chinese  598  1089  1399  1878  265  1036  1323  1628  333  1150  1484  1968 
    SE Asia  471  1078  1361  1864  195  1012  1266  1585  283  1108  1435  1922 
 ApoB  mg/L  0.00  Asia All  2884  541  849  1329  1278  570  908  1371  1608  522  810  1256 
 ApoE  mg/L  0.07  Asia All  2872  25  41  64  1275  25  39  62  1602  26  42  66 
 LP(a)  mg/L  0.10  Asia All  2891  2  99  689  1278  1  90  692  1612  3  108  648 
 LIP  U/L  0.11  Asia All  2875  13  24  39  1270  13  23  41  1595  14  25  39 
 IgE  × 10 3 IU/L  0.21  Asia All  1259  2  42  528  559  3  61  633  700  2  33  390 
 SAA  mg/L  0.31  Asia All  2846  1.0  3.8  20.4  1257  1.1  3.7  23.5  1589  1.0  3.9  18.3 
    Japanese  1698  0.9  3.2  16.4  767  0.9  3.3  16.4  930  1.0  3.2  15.9 
    Chinese  595  1.4  4.8  22.9  265  1.3  4.7  27.8  331  1.4  4.9  21.3 
    SE Asia  477  1.4  5.7  24.7  193  1.4  5.5  22.3  281  1.6  5.7  25.2 
 RBP  mg/L  0.16  Asia All  2887  17.4  28.2  47.5  1273  21.9  33.4  49.7  1604  17.3  24.5  40.3 
 ASO  × 10 3 IU/L  0.30  Asia All  2879  2  37  293  1272  3  37  315  1611  1  39  248 
    Japanese  1730  1  38  292  778  2  37  343  946  2  36  295 
    Chinese  592  1  27  159  264  2  29  193  334  1  26  163 
    SE Asia  477  10  60  332  195  8  61  316  281  11  63  308 
 sTf-R  nmol/L  0.20  Asia All  2853  10.2  15.0  28.3  1262  10.4  14.9  23.9  1574  10.7  15.5  34.4 
 Ferritin  µ g/L  0.29  Asia All      1266  22  115  348  1606  3  23  124 
    Japanese      764  24  102  268  949  3  18  121 
    Chinese      265  28  152  442  332  3  28  158 
    SE Asia      191  39  162  499  282  5  38  159 
 EPO  IU/L  0.13  Asia All  2859  4.0  8.4  22.1  1269  3.8  7.7  15.8  1586  3.9  9.1  25.4 
 VitB12  ng/L  0.18  Asia All  2869  135  347  779  1270  123  312  705  1599  152  377  821 
 Folate  µ g/L  0.68  Asia All  2840  10.1  21.8  56.4  1262  9.1  19.5  44.6  1591  11.5  24.0  67.2 
    Japanese  1701  9.4  19.2  40.0  777  8.7  17.4  34.7  930  10.8  20.8  46.0 
    Chinese  599  12.6  28.3  72.8  267  11.8  24.6  58.4  332  14.1  31.6  82.2 
    SE Asia  477  13.3  29.7  72.5  195  12.0  25.5  61.1  282  14.5  33.5  74.2 
 AFP  µ g/L  0.00  Asia All  2859  1.1  2.5  6.5  1271  1.2  2.7  6.8  1590  1.0  2.4  6.4 
 CEA  µ g/L  0.10  Asia All  2880  0.4  1.3  4.1  1264  0.4  1.6  4.4  1606  0.4  1.1  3.4 
 CA19-9  × 10 3 IU/L  0.14  Asia All  2887  0.8  6.4  30.0  1276  0.8  5.2  24.5  1608  0.9  7.6  33.3 
 CA125  × 10 3 IU/L  0.00  Asia All      1267  3.2  7.5  16.2  1588  4.2  11.9  42.4 
 CA15-3  × 10 3 IU/L  0.35  Asia All  2853  4.0  6.5  19.2  1276  4.0  7.0  18.8  1583  3.9  6.1  19.3 
    Japanese  1726  3.8  6.1  17.4  775  4.1  6.7  17.8  942  3.8  5.7  16.4 
    Chinese  592  4.2  6.9  20.4  266  4.5  7.3  19.6  331  3.9  6.5  20.0 
    SE Asia  478  4.0  8.3  19.9  196  4.4  9.2  21.3  284  3.8  7.6  20.4 
 PSA  µ g/L  0.04  Asia All      1271  0.32  0.88  2.77  1596  0.000  0.005  0.038 
 PG1  µ g/L  0.06  Asia All  2834  22  42  85  1255  25  46  95  1584  22  39  81 
 PG2  µ g/L  0.00  Asia All  2842  4  8  29  1248  4  9  26  1585  4  8  30 
 PG1/PG2   0.00  Asia All  2850  2.1  5.1  7.9  1260  2.0  5.3  8.1  1590  1.9  5.0  7.6 
 DHEA-S  mmol/L  0.00  Asia All      1273  2.4  6.1  12.1  1602  1.0  3.9  9.1 
 PRL  µ g/L  0.04  Asia All  2862  4  10  29  1272  4  9  21  1591  5  12  33 
 LH  IU/L  0.00  Asia All      1272  1  3  7  1588  1  7  71 
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 International unit  n  Male + Female  n  Male  n  Female 
 Analytes  Units  SDR-reg  Area  LL  Me  UL  LL  Me  UL  LL  Me  UL 
 FSH  IU/L  0.00  Asia All      1263  2  5  14  1597  2  8  173 
 TSH  mU/L  0.16  Asia All  2872  0.4  1.4  4.0  1263  0.4  1.4  3.8  1599  0.4  1.5  3.9 
 FT4  pmol/L  0.04  Asia All  2879  9.2  11.7  14.6  1273  9.4  11.9  14.9  1607  9.1  11.5  14.2 
 FT3  pmol/L  0.00  Asia All  2872  38.6  4.56  5.50  1272  4.05  4.73  5.90  1596  3.80  4.43  5.31 
 Tg  µ g/L  0.14  Asia All  2869  1  9  30  1248  2  9  30  1597  1  9  32 
 Insulin  mIU/L  0.24  Asia All  2858  1.8  4.6  11.8  1239  2.1  4.8  13.5  1599  1.9  4.4  10.8 
 Adiponectin  mg/L  0.36  Asia All  2861  3.7  9.5  22.8  1254  3.4  7.5  16.2  1590  4.7  11.5  24.0 
    Japanese  1296  4.2  10.9  23.6  467  3.7  8.3  17.2  824  5.7  12.7  25.6 
    Chinese  527  3.7  9.5  19.4  216  3.3  7.6  14.5  311  5.5  11.2  22.2 
    SE Asia  414  3.0  7.5  16.3  159  2.6  5.9  12.4  258  3.8  8.6  18.8 
 PTH  ng/L  0.41  Asia All  2866  21  45  92  1271  21  44  89  1598  21  45  97 
    Japanese  1720  23  48  96  779  23  48  93  943  24  49  101 
    Chinese  594  18  38  70  265  19  37  68  329  18  38  73 
    SE Asia  475  17  40  94  193  20  42  83  280  16  39  98 
 BoneALP  µ g/L  0.00  Asia All  2869  6.4  11.4  20.6  1267  7.5  12.5  22.5  1601  6.2  10.5  19.1 
 TRAP-5b  U/L  0.30  Asia All  2814  0.8  1.8  3.7  1247  0.9  2.0  3.8  1563  0.7  1.6  3.5 
    Japanese  1676  0.8  1.9  4.0  764  1.0  2.1  4.2  915  0.8  1.7  3.8 
    Chinese  585  0.7  1.5  3.1  263  0.8  1.7  3.2  325  0.6  1.4  3.1 
    SE Asia  471  0.7  1.7  3.7  193  1.1  2.0  3.8  277  0.7  1.5  3.6 
 When the standard deviation ratio due to region (SDR-reg) is 0.25, the RIs are computed in four ways: from the entire data (Asia All), 
Japanese, Chinese, and Southeast Asian (including Ho Chi Minh City, Kuala Lumpur, and Jakarta) (SE Asia). 
( Table 3   Continued )
 Table 4   Reagent manufacturers involved in the cross-comparison of 
results measured by immunoassays. 
  Roche  Abbott  Tosoh  Siemens  BC  Fuji  Misc 
 Ferritin  6  8  2  1  1  1  5 
 AFP  10  9  2  3  2  3  2 
 CEA  10  9  2  3  2  3  2 
 CA19-9  11  8  1  1  1  3  2 
 CA125  12  9  1  1  0  3  2 
 PSA  11  10  1  0  2  1  2 
 Estradiol  7  5  2  2  0  0  1 
 Progesterone  3  3  1  1  0  0  0 
 Testosterone  3  2  2  2  0  0  0 
 PRL  5  7  3  2  2  0  1 
 FSH  5  8  3  2  2  0  1 
 LH  5  8  3  2  2  0  1 
 TSH  11  12  2  4  0  0  1 
 FT4  11  12  2  4  0  0  1 
 FT3  9  11  2  3  0  0  1 
 Insulin  6  6  6  2  1  2  1 
 Cortisol  3  0  3  1  3  0  2 
 PTH  7  0  1  3  0  0  0 
  135  127  39  37  18  16  25 
 Abbott, Abbott Diagnostics; BC, Beckman Coulter; Fuji, Fujirebio 
Diagnostics; Misc, miscellaneous; Roche, Roche Diagnostics; 
Siemens, Siemens Healthcare Diagnostics; Tosoh, Tosoh Bioscience. 
those of  Figure 2 , and the other for the commercial QC 
specimens (red circle or cross). These results clearly indi-
cate that commutable specimens such as freshly prepared 
sera from healthy volunteers are essential to make cross-
comparisons of test results aimed at transferring RIs by 
the regression procedure. 
 Discussion 
 A multicenter study for derivation of RIs can be con-
ducted by either of two schemes. One is by individual 
measurement by collaborating laboratories and integra-
tion of test results to derive common RIs. The other is by 
centralized measurement and derivation of RIs, followed 
by transference of RIs to the collaborating laboratories 
with or without cross-comparison of test results. The 
former scheme can be applied to a study that only targets 
standardized analytes. However, when non-standardized 
analytes are included, it is essential to apply the latter 
scheme. The present study is the first multicenter study 
of reference values to include non-standardized analytes 
measured by immunoassays. There was, however, some 
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 Figure 2   Cross-comparison of test results between the central and three local laboratories. 
 Typical results of cross-comparison of four non-standardized analytes (AFP, CA19-9, PSA, and TSH). The x-axis represents test results by the 
central laboratory, and the y-axis represents results obtained at the three local laboratories. The comparison was made in conventional unit.
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 Figure 3   Commutability of commercial QC specimens in the cross-comparison. 
 Typical results of the cross-comparison plotted for two datasets: one for individual sera (black dots), as in those of Figure 1, and the other 
for the commercial QC specimens (red circle or cross, distinguishing the sources). The comparison was made in conventional unit.
hesitancy among would-be collaborating laboratories to 
take part in this study with no expected benefit unless the 
same reagents/platforms as those in the central labora-
tory were used. Therefore, it was needed to cross-compare 
test results between the central and local laboratories, 
and a service for transferring RIs to the participating labo-
ratories based on the cross-comparison results by use of 
the reduced major axis regression was planned. 
 The precision of converting RIs depends primarily 
on the SE of the slope, SE(b), which in turn depends on 
both the correlation coefficient and the sample size used 
for the comparison, as expected from Equation (5) (also 
refer to Appendix 1). It is obvious that with increases in 
the data size  n and/or the correlation coefficient  r , the 
precision of the conversion improves. For the standard-
ized comparison, we chose to use  CV(b) by dividing it by 
the slope b. 
 Regarding the critical limit for providing the conver-
sion service, it is difficult to set a fixed value that is suita-
ble to all situations. This is because the precision depends 
not only on  n and  r described above but also on analytical 
variations and the range of the RI (LL – UL) relative to its 
median (see below). Therefore, we inspected all the cross-
check test results and checked for the behavior of CV(b) in 
relation to the data size and the degree of scatter around 
regression line. Then, we set CV(b) = 10% empirically, as 
the critical value by consensus among the coordinators of 
the study. To demonstrate the performance of CV(b) and 
the implication its cut-off value, all pair-wise comparison 
made for four analytes are displayed in Supplementary 
Figure 2 as a reference. On the basis of the approximated 
formula, Equation (6), for the typical data size of n = 20, 
30, and 40, CV(b) = 10% corresponds to  r = 0.906, 0.849, 
and 0.787, respectively, indicating that uncertainty of the 
conversion is equivalent for the three cases despite rela-
tively large change in the  r value. 
 The number of specimens used for the comparison 
was in most cases  < 40, less than that described in the CLSI 
guideline (EP9-A2) entitled  ‘ Method comparison and bias 
estimation using patient samples ’ [ 6 ]. Duplicate meas-
urement as recommended in the guideline was also not 
done for the comparison. However, we obtained very low 
CV(b) of below 5% in most of the standardized analytes, 
a situation where we apparently do not need that many 
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specimens for the comparison, with the notable exception 
of sodium (Na), chloride (Cl), potassium (K), total calcium 
(Ca), and albumin (Alb), which showed CV(b) of  > 10%, as 
discussed below. 
 At any rate, we probably have to stratify the level of 
strictness in setting the acceptability criteria for the cross-
comparison in the multicenter study. It varies from a situa-
tion where one just needs to confirm transferability of the 
RIs centrally determined to a situation where a regulatory 
group requests strict criteria for the transference. In fact, 
what we aimed at by the cross-comparison was to meet the 
need of the former situation, and thus, most laboratories 
were pleased with provision of the transference service. 
 However, we realized that it was very important not 
to measure all specimens for the cross-comparison in a 
single day. They should have been measured in two or 
more parts on separate days so that between-day varia-
tions of test results be considered in deriving the regres-
sion line. 
 As expected, the test results for the non-standardized 
analytes depended on reagent types and showed sys-
tematic bias between the central and local laboratories 
in the majority of cases. However, CV(b)s observed for 
the analytes mostly measured by immunoassays were as 
low as those for the standardized analytes, with 43% of 
them attaining a CV(b) of  < 5%. This observation should 
have great relevance in considering harmonization of test 
results of those analytes. In fact, an international forum 
called  ‘ Improving Clinical Laboratory Testing through 
Harmonization ’ was held in October, 2010, in Gaithers-
burg, MD, USA, and the topic of harmonization of immu-
noassays has become an urgent global issue in the clinical 
chemistry societies [ 7 ]. It appears obvious that an indis-
pensable step for harmonization is comparative meas-
urement of a panel of commutable specimens or a set of 
multiple individual sera across reagents/platforms in the 
market. Then, the clinical chemical societies can find a 
way to build consensus among reagent manufacturers on 
how to align test results based on the comparison. 
 The large scatter around the regression line observed 
for TP, Alb, and the electrolytes (Supplementary Table 5) is 
mostly attributable to the narrow range (UL‒LL) of each RI 
relative to the mid-point ((LL + UL)/2) of the RI, as was pre-
dicted by Linnet based on his simulation study to evalu-
ate required number for samples for the method compari-
son [ 8 ]. This implies that a small change in the test result 
causes a large relative fluctuation in the cross-comparison 
using specimens limited to healthy individuals. Actually, 
the unit for reporting values of Na and Cl is 1 mmol/L, and 
their RIs cover a range of only 6 units (140 – 146 mmol/L) 
and 8 units (100 – 108 mmol/L), respectively. Thus, there 
exists a large round-up error for the last digit in report-
ing test results: i.e., a difference of one unit (1 mmol/L) 
corresponds to 16.7% and 12.5% of the range of RIs for Na 
and Cl, respectively. Similar situations exist for TP, Alb, K, 
and total Ca: a 1-unit change in the reported value makes 
a difference of 6.7%, 11.1%, 9.1%, and 7.7% of the range of 
RIs, respectively. 
 From these theoretical considerations, the success of 
the transference of RIs on the basis of cross-comparison 
using specimens from healthy individuals depends on: 1) 
a wider range of the RI (UL‒LL) relative to the median of 
the RI; 2) a larger sample size  n used for the comparison; 
and 3) a higher correlation coefficient  r . It is also impor-
tant to make a visual check for outlying data points which 
affect the regression line. 
 As for the regionality prominently observed for folate, 
we assume this will be attributable to the genetic differ-
ences in enzymes that are involved in processing folate in 
the body [ 9 ]. This is because supplementation of folate is 
not a common practice in East and Southeast Asia, even 
for women in the reproductive age. Actually, the pattern of 
regionality (higher values in Taiwan, Hong Kong, Ho Chi 
Minh City, and Jakarta) appears similar for both males and 
females. The possibility of higher consumption of green 
vegetables in those countries appears unlikely because 
regionality is still clearly observed even after adjusting for 
the level of vegetable consumption recorded in the ques-
tionnaire by multiple regression analysis (this finding will 
be reported in the third companion paper to be submit-
ted in this series). In regard to the regionality observed for 
CA15-3, PTH, and adiponectin, we can only attribute them 
to genetic differences in concentrations of those proteins 
in blood. 
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Hong Kong; 5) Macau Institute for Applied Research in Med-
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tute, Kuala Lumpur; 12) Gleneagles Intan Medical Centre, 
Kuala Lumpur; and 13) Medic-Lab, Ho Chi Minh City. 
 Inside Japan: 14) Keiyu Corp. Yoshida Hospital, Asa-
hikawa; 15) Hokkaido University, Sapporo; 16) Kishimoto 
Clinical Laboratory, Tomakomai; 17) Iwate Medical School, 
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Tokyo; 26) Shinshu University, Matsumoto; 27) Yamanashi 
University, Kofu; 28) Nagoya University, Nagoya; 29) Anjo 
Kosei Hospital, Anjo; 30) Fujita Health University, Toyoake; 
31) Osaka University, Suita; 32) Tenri Hospital, Tenri; 33) 
Osaka Municipal University, Osaka; 34) National Car-
diovascular Center, Suita; 35) Kawasaki Medical School, 
Kurashiki; 36) Kurashiki Central Hospital, Kurashiki; 37) 
Okayama University, Okayama; 38) Okayama Medical 
Laboratory, Kurashiki; 39) Yamaguchi University, Ube; 
40) Tokuyama Central Hospital, Shunan; 41) Yamaguchi 
Prefectural Medical Center, Hofu; 42) Saiseikai Yamaguchi 
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 Appendix 1 
Estimation of standard error of slope  b by 
the reduced major axis regression 
 Assuming a dataset consisting of  n points of data pair ( x and 
 y ), the reduced major axis regression is expressed as follows: 
 ( )y y b x x− = −  
 where  x,  y  represents the means of  x and  y . The slope  b 
is derived as follows: 
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 The mathematical method to derive standard error 
(SE) of  b, SE ( b ), is not known and commonly approxi-
mated by SE of slope  b ′ ,  SE ( b ′ ), by the ordinary least-
square method by the following formula (references 2, 4). 
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 where  s represents the standard deviation of data points 
around the ordinary least-square regression line.  s is 
derived as follows with  Y representing a predicted  y for a 
given  x , or  ( )Y y b x x= + −′ , and  r representing the correla-
tion coefficient. 
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 Using the last formula, approximated  SE ( b ) can be 
expressed as follows. 
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 Therefore, CV of slope  b , or  CV ( b ), can be expressed 
as follows: 
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